Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29645710 | 1.00 | LMNA (0.40) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL22981252 | 1.00 | LMNA (0.40) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL29645848 | 1.00 | LMNA (0.40) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL22979834 | 1.00 | LMNA (0.40) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL29645432 | 0.90 | TP53 (0.42) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL29646172 | 0.90 | TP53 (0.42) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL22979291 | 0.90 | TP53 (0.42) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL22979288 | 0.90 | TP53 (0.42) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL22981120 | 0.90 | TP53 (0.42) | LMNAGAAALPLKMT2AALPI | |
| SCHEMBL22981167 | 0.90 | MAPT (0.43) | LMNAGAAALPLKMT2AALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | claimed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | claimed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | claimed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | LMNA 2937/4885GAA 3740/4885ALPL 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.